ACR Convergence 2026 Archives - ACR Meeting Abstracts

Abstract Number: 2364

Ianalumab reduces disease activity across ESSDAI domains: Post hoc analysis from the pooled Phase-3 NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease
Abstract Number: 1953

ICOS and OX40 Define Divergent CD4⁺ T Cell Programs in Rheumatoid Arthritis.
Abstract Number: 0489

Identification and Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results from a Nationwide Patient Database
Abstract Number: 2064

Identification of a Novel Non-Canonical STING-IL1β Axis Activated by Lupus Patient Serum
Abstract Number: 2072

Identification of Differentially Expressed Proteins in Rheumatoid Arthritis-Interstitial Lung Disease with Shared Fibrotic Biology in Systemic Sclerosis-Interstitial Lung Disease via Plasma Proteomic Profiling
Abstract Number: 0032

Identification of Mitochondrial Autoantibody Signatures Associated with Cellular Bioenergetic Dysfunction in Systemic Sclerosis
Abstract Number: 2813

Identification of Novel Candidate Biomarkers for Kawasaki Disease Using Large-scale Affinity Proteomics
Abstract Number: 2365

Identification of Protein Signatures of Sjögren’s Disease Activity and Their Modulation by Deucravacitinib in Anti-SSA Positive Patients with SLE: Results from a Phase 2 Study
Abstract Number: 0879

Identification of Protein Signatures Tracking Changes of Disease Activity of PsA Disease Domains and Improvement With Deucravacitinib Treatment in Phase 3 Clinical Studies
Abstract Number: 2208

Identification of Proteomic Signatures Associated With Global and Domain Specific Disease Activity in SLE and Their Modulation by Deucravacitinib in a Phase 2 Study
Abstract Number: 2036

Identification of Rheumatoid Arthritis Patient Subsets Responsive to TNF Inhibitory Therapy by Transcriptomic-Based Endotyping of Synovial Tissue
Abstract Number: 0952

Identification of risk factors for renal crisis and chronic kidney dysfunction in patients with systemic sclerosis
Abstract Number: 0424

Identification of Selective Cognitive Dysfunction Profiles and Disease-Specific Neuroimaging Biomarkers in Sjogren’s Disease
Abstract Number: 1003

Identification Of Transcriptomic Biomarkers Associated With Obstetric Complications In Systemic Lupus Erythematosus
Abstract Number: 1511

Identifying Barriers to Optimal School Function Among Youth with Juvenile Idiopathic Arthritis: Perspectives from Stakeholders
Abstract Number: 0425

Identifying Clinical Manifestations for Daily Life Impairment through K Means Cluster Analysis in Sjögren’s Disease
Abstract Number: 1381

Identifying Educational Gaps in Salivary Gland Ultrasound for Sjögren’s Disease
Abstract Number: 0658

Identifying inflammatory myopathies from electronic health record data with natural language processing and machine learning
Abstract Number: 0638

Identifying Patterns of Frequent Knee Pain: Data from the Osteoarthritis Initiative
Abstract Number: 2433

Identifying Rheumatoid Arthritis Patients at Risk for CT-Defined Low Muscle Mass Using Routine Clinical Data
Abstract Number: 1190

Identifying the mechanisms of reduced exercise capacity in systemic sclerosis with exercise cardiac magnetic resonance imaging
Abstract Number: 1620

Idiopathic Granulomatous Mastitis as an Immune-Mediated Inflammatory Disease: Clinical Phenotype, Treatment Exposure, Safety, Recurrence, and Long-Term Outcomes in a 154-Patient Latin American Cohort
Abstract Number: 2628

Idiopathic Granulomatous Mastitis: Clinical Characteristics, Management and Outcomes in Sigle-Center Cohort
Abstract Number: 1004

IFN-I-driven expansion of Ly6Chi CCR2+ myeloid cells promotes myocardial injury in lupus
Abstract Number: 2674

IgA Nephropathy in the Setting of TNF-alpha Inhibitor Use and Behcet’s Disease: Drug Effect or Disease Manifestation?
Abstract Number: 0984

IgG Autoantibodies to Heparan Sulfate on a subset of Membrane-Bound HSPGs in Anti-Topoisomerase I-Positive Systemic Sclerosis
Abstract Number: 2892

IgM PR3-Autoreactive B Cells in ANCA-Associated Vasculitis
Abstract Number: 2782

IL-17 Inhibitors vs Anti-TNF Agents in Severe Hidradenitis Suppurativa: A Single-Centre Retrospective Analysis
Abstract Number: 0362

IL-17 Pathway Inhibitors in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis of Efficacy, Safety, Treatment Rankings, and Certainty of Evidence
Abstract Number: 0033

IL-1β Primes Liver Receptor Homolog-1-Mediated Profibrotic Fibroblast Activation in Systemic Sclerosis
Abstract Number: 1854

IL-33 blockade limits gut-joint trafficking of IL-17A-producing MAIT, Th17 and TRM cells in experimental spondyloarthritis
Abstract Number: 1750

IL-6 Inhibitors Demonstrate the Highest Observed Metabolic Adverse Event Signal Among Rheumatologic Biologics
Abstract Number: 0454

IL-6/TNFα-neutralizing CD19 CAR T-cell therapy in difficult-to-treat rheumatoid arthritis: Long-term follow-up and immune remodeling
Abstract Number: 2209

IMC-002 (IMM0306), a bispecific CD20×CD47 fusion protein, demonstrates improvements in active Systemic Lupus Erythematosus patients in a phase Ib/II study
Abstract Number: 2675

Immune Checkpoint Inhibitor Exposure and Risk of Incident Polymyalgia Rheumatica and Giant Cell Arteritis: A Global Federated Network Study
Abstract Number: 2676

Immune Checkpoint Inhibitor Inflammatory Arthritis: Initial Steps in External Validation of Claims-based Algorithm via Single-center Chart Review
Abstract Number: 1680

Immune Checkpoint Inhibitor Myositis, Myocarditis, and Myasthenia Gravis: a comparison of overall survival using real world data
Abstract Number: 1681

Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Is Commonly Persistent and Steroid-Dependent: A Systematic Review
Abstract Number: 1137

Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica, Giant Cell Arteritis, and Large-Vessel Vasculitis: A Systematic Review
Abstract Number: 0741

Immune Checkpoint Inhibitor-induced Raynaud’s Phenomenon: A Descriptive Cohort Study with Cytokine Characterization
Abstract Number: 0941

Immune Checkpoint Inhibitor-Induced Sicca: Senescence-Driven Acinar-to-Ductal Metaplasia via Jagged2-Notch2 Signaling as a Candidate Therapeutic Target
Abstract Number: 2629

Immune response to recombinant herpes zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases – a prospective longitudinal study over 12 months
Abstract Number: 2037

Immunization with Malondialdehyde-Acetaldehyde-Modified Vimentin Uniquely Induces Humoral and T-Cell-Mediated Immunity to Citrullinated Proteins in Arthritis-Prone Mice
Abstract Number: 2109

Immunogenicity and Impact of Anti-Drug Antibodies on the Efficacy and Pharmacokinetics of Inebilizumab in a Phase 3 Trial in IgG4-Related Disease
Abstract Number: 2630

Immunological Heterogeneity in Ocular and Systemic Sarcoidosis: Insights from Biopsy-Proven Disease
Abstract Number: 2210

Immunological responses following daratumumab treatment in lupus nephritis patients
Abstract Number: 2084

Immunometabolic changes associated with sustained remission in patients with SLE and JDM treated with anti-CD19 CAR-T cells
Abstract Number: 0315

Immunophenotypic Shifts in CD8 and γδ T Cells Help Discriminate Lupus Nephritis Patients with Minimal Proteinuria from Non-Lupus Nephritis SLE and High Proteinuria Lupus Nephritis Patients
Abstract Number: 0106

Immunoproteomic Profiling of Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
Abstract Number: 0742

Immunosuppression Prescriber Patterns in Patients on Immune-Checkpoint Inhibitors: Real World Data Shows DMARD Use is Uncommon
Abstract Number: 1317

Impact of 2 Years of Bimekizumab Treatment on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis: An Integrated Analysis from a Phase 3 Study and its Open-Label Extension
Abstract Number: 2477

Impact of a Structured Educational Intervention on Osteoporosis Screening Among Internal Medicine Residents and Faculty: A Quality Improvement Study
Abstract Number: 2253

Impact of Achieving Low Disease Activity or Remission on Flares, Patient-Reported Symptoms, and Work Productivity Among Patients With Systemic Lupus Erythematosus
Abstract Number: 2160

Impact of age and sex on drugs prescription and effectiveness in systemic sclerosis – an EUSTAR longitudinal analysis
Abstract Number: 0426

Impact of Ambient Air Pollution on Symptomatology, Systemic Activity, and Disease Progression in Sjögren Disease: Results from the ASSESS Cohort
Abstract Number: 2540

Impact of an Integrated Primary Care-Rheumatology Referral Pathway on Diagnostic Delay in Axial Spondyloarthritis: Results from the EspAnde Project
Abstract Number: 0551

Impact of an Online Virtual Patient Simulation – Overcoming Clinical Inertia in Rheumatoid Arthritis Care After TNF Inhibitor Failure
Abstract Number: 2783

Impact of ANA/ENA Serologic Result Patterns on Rheumatology Referrals and Diagnostic Yield
Abstract Number: 0118

Impact of Anti-TNF Treatment on Muscle Metabolism in Rheumatoid Arthritis: Six-Month Data
Abstract Number: 1409

Impact of Baseline Disease Activity on Sarilumab Response: Extended Post-hoc Analyses of Dose and Treatment Regimen Across Baseline CDAI Strata in Phase III Trials
Abstract Number: 0427

Impact of comorbid conditions and family history on patient-reported outcomes in Childhood-onset Sjögren’s Disease (cSjD)
Abstract Number: 2296

Impact of Deucravacitinib Treatment on Cardiovascular Risk-Associated Scores and Biomarkers in Patients With Active Psoriatic Arthritis Results From Phase 3 Studies
Abstract Number: 1106

Impact of Deucravacitinib, a Tyk2 Inhibitor, on Epithelial Cells Function in Sjögren’s Disease in a Salivary Gland Organoid Models
Abstract Number: 0599

Impact of Disease Activity, Diagnosis, and Glucocorticoid Use on the Attitudes about Glucocorticoids in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 2333

Impact of Expert Sacroiliac MRI Reassessment in Patients Referred for Clinical-Radiological Discordance in Suspected Axial Spondyloarthritis
Abstract Number: 1410

Impact of GLP-1 Receptor Agonist Therapy on Clinical Disease Activity Index in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 1621

Impact of GLP-1 Receptor Agonist Use on Clinical Outcomes in Patients with Pulmonary Sarcoidosis and Concurrent Type 2 Diabetes or Obesity: A Propensity Score-Matched Federated Network Analysis
Abstract Number: 0816

Impact of HLA‑B27 on Clinical Presentation and Imaging in Axial Spondyloarthritis in Latin America: Insights from the ESPALDA-PANLAR Registry
Abstract Number: 2803

Impact of Lifestyle Intervention on Immune Signaling in Older Adults with Rheumatoid Arthritis
Abstract Number: 1224

Impact of Lupus Nephritis Flares on Healthcare Utilization: A Retrospective Cohort Study in the United States Between 2016 and 2025
Abstract Number: 2722

Impact of Medicaid Expansion on Healthcare Spending in Rheumatoid Arthritis: A Difference-in-Differences Analysis
Abstract Number: 2631

Impact of Metformin on Cardiopulmonary Outcomes in Sarcoidosis: A Global Retrospective Cohort Study Using TriNetX
Abstract Number: 1785

Impact of Multimodal Intervention on Shingrix Vaccination Rate and Herpes Zoster Incidence Among Patients on JAK or IL-6 Inhibitors
Abstract Number: 2542

Impact of Neuropathic-like and Nociplastic Pain on Mental Health and Sleep in Inflammatory Arthritis: Results from the NEUPIA Study
Abstract Number: 2254

Impact of Obstructive Sleep Apnea on Clinical Outcomes in Systemic Lupus Erythematosus and the Effect of SGLT2i and GLP-1RA Therapies on OSA Development
Abstract Number: 0909

Impact of Post-Traumatic Stress Disorder on Clinical Outcomes in Autoimmune Diseases: A 5-Year Propensity-Matched Cohort Study
Abstract Number: 0490

Impact of RA disease activity on pulmonary outcomes in patients with RA-ILD : data from the prospective cohort TRANSLATE 2
Abstract Number: 2255

Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Venous Thromboembolism in Systemic Lupus Erythematosus
Abstract Number: 0455

Impact of Rheumatoid Factor Levels on Drug Survival of Certolizumab and Adalimumab in Rheumatoid Arthritis: A Real-World Cohort Study
Abstract Number: 0201

Impact of rituximab-induced hypogammaglobulinemia on relapse risk in patients with ANCA-associated vasculitis
Abstract Number: 2577

Impact of Seropositivity on Post-Operative Complications Following Total Hip and Total Knee Arthroplasty in RA: A Retrospective Cohort Study
Abstract Number: 1535

Impact of Sex on Systemic Lupus Erythematosus: Comparative Analysis of Accumulated Organ Damage and Patient-Reported Outcomes
Abstract Number: 2110

Impact of Smoking on Clinical Outcomes in IgG4-Related Disease: A Propensity Score-Matched Analysis of a Large Federated Health Network
Abstract Number: 0521

Impact of Systemic Sclerosis on Inpatient Outcomes and Healthcare Utilization in Pulmonary Hypertension: A Nationwide Study
Abstract Number: 1177

Impact of T-Cell Engager Therapy on Digital Vasculopathy and Hand Function in Patients with Treatment-Refractory Systemic Sclerosis
Abstract Number: 1815

Impact of the 2023 ACR/EULAR Classification Criteria on Long-Term Outcomes in a Large Thrombotic Antiphospholipid Cohort
Abstract Number: 2173

Impact of the CD19 Cellular Therapies on Nailfold Videocapillaroscopy in Patients with Systemic Sclerosis
Abstract Number: 2723

Impact of the Full-Scale War on Rheumatology Clinical Trials in Eastern Ukraine: Structural Challenges, Bioethical Considerations, and Adaptation of Clinical Trial Activity
Abstract Number: 0428

Impact of the recall period on the scoring of patient-reported outcomes in Sjogren disease: ESSPRI, SSSD, and patient global assessment
Abstract Number: 0491

Impact of Time to Therapeutic Response on the Risk of Chronic Pain, Fibromyalgia, Fatigue, Anxiety and Depression in Patients with Early Rheumatoid Arthritis (ESPOIR Cohort)
Abstract Number: 0792

Impact of Transition Readiness Planning: A Retrospective Cohort Analysis from a Single Center Rheumatology Department
Abstract Number: 1318

Impact of Treat-to-Target Goals at Baseline on Achieving Disease Control Through 12 Months in Patients with Moderate-to-Severe Rheumatoid Arthritis Treated with Upadacitinib: Post Hoc Analysis from the UPHOLD Real-World Study
Abstract Number: 1751

Impact of unmet workplace accommodation needs on work productivity in those with systemic sclerosis gastrointestinal involvement
Abstract Number: 1382

Impact on Productivity of Sjögren’s Disease in Swedish Patients – A Nationwide Cohort Study Between 2006 and 2022
Abstract Number: 0985

Impaired ZIP8-Mediated Zinc Signaling Promotes Fibrosis in Systemic Sclerosis
Abstract Number: 2467

Implementation and early outcomes of a psycho-rheumatology clinic in a University Hospital.
Abstract Number: 1662

Implementation of an electronic medical records-based prompt was associated with a significant improvement in aPL testing compliance and lower observed thrombotic events in SLE patients
Abstract Number: 2525

Improved Transition Readiness in ACCORD (The Adult Center for Childhood Onset Rheumatic Disease) – a Rheumatology Clinic Dedicated to Health Care Transition
Abstract Number: 1860

Improvement in Executive Function Following Nipocalimab Treatment in Patients with Sjögren’s Disease: A Randomized Clinical Trial
Abstract Number: 2211

Improvement in Laboratory Markers of Disease Activity with Dapirolizumab Pegol Treatment in Patients with Systemic Lupus Erythematosus: Updated Analyses from a 48-Week Phase 3 Trial
Abstract Number: 1319

Improvement in the Axial Domain With Deucravacitinib Through Week 52 in Patients With PsA and Axial Involvement: 2 Randomized, Controlled Phase 3 Trials
Abstract Number: 0238

Improvement of nailfold capillaroscopy pattern over time is associated with less disease progression in patients with systemic sclerosis: a EUSTAR study
Abstract Number: 2212

Improvements in SLE Disease Activity Across Multiple Organ Systems with Intravenous and Subcutaneous Anifrolumab Treatment: Pooled Analysis of 3 Phase 3 Trials
Abstract Number: 0768

Improving Access to Orthopedic Surgery for Benefit Insured and Underinsured Patients: Early Outcomes of a Hybrid Ambulatory Care Center Model
Abstract Number: 2478

Improving Access to Pediatric Rheumatology Medical Education
Abstract Number: 2677

Improving Lipid Profile Monitoring in Patients Initiating JAK Inhibitors for Rheumatoid and Psoriatic Arthritis
Abstract Number: 1565

Improving Osteoporosis Screening in Patients on Chronic Glucocorticoid Therapy: A Quality Improvement Initiative in a Rheumatology Teaching Clinic
Abstract Number: 1724

Improving Post-Fracture Osteoporosis Care: Lessons from an Electronic Health Records Based Multidisciplinary Care Delivery Intervention
Abstract Number: 1345

Improving Psoriatic Arthritis Referrals from Dermatology to Rheumatology Through Electronic Health Record-Integrated Digital Screening
Abstract Number: 1448

Improving recognition of multisystem complications in rheumatoid arthritis: Can generative AI bridge the clinical gap?
Abstract Number: 2459

Improving Reproductive Health Counseling and Screening in a Pediatric Rheumatology Clinic by Involving a Diverse Group of Stakeholders
Abstract Number: 1536

Improving Research Accelerated by You (RAY) Lupus Registry Recruitment Among Historically Underrepresented People Living with Lupus: A Multi-Phase Communication Development and Validation Study
Abstract Number: 1803

Improving Self-Care in Inflammatory Rheumatic Diseases Through an Adaptive Digital Training Platform: Results of the Randomized, Controlled RhPID Study
Abstract Number: 2479

Improving Small Joint Examination Competency Among Internal Medicine Trainees: A Resident-Led Quality Improvement Initiative
Abstract Number: 0429

In Anti-SSA-Positive Sjögren’s Disease, Labial Biopsy Focus Score Is Associated with B-cell-Axis Serologies, but Not with Clinical Disease Manifestations
Abstract Number: 1107

In vivo CD19 CAR T Cells Generated By Targeted Lipid Nanoparticles Induce Deep, Durable, and Robust B cell Depletion Resulting In Immune Reset In Non-Human Primates
Abstract Number: 1225

In Vivo CD19 Chimeric Antigen Receptor T Cells Show Excellent Safety and Preliminary Efficacy in Refractory Systemic Lupus Erythematosus Treatment
Abstract Number: 0147

In vivo comparisons of two designs of T-cell engagers : toward improved TCE design in autoimmunity
Abstract Number: 2085

In Vivo Engineering of CD19 CAR-T Cells Using CD8-Targeted Lipid Nanoparticles: A Potential Breakthrough for Treatment of Autoimmune Disease
Abstract Number: 0148

In Vivo Generation of CD19/BCMA Dual-targeting CAR-T for Autoimmune Diseases
Abstract Number: 2086

In vivo TRAC-CAR T cell engineering via cell-selective delivery and genomic locus-specific integration results in immune reset in non-human primates
Abstract Number: 2957

Inadequate response to Denosumab: differences between patients with incidental fractures and/or bone loss during treatment
Abstract Number: 0659

Inadequate Screening For Malignancy In High Risk Patients With Inflammatory Myositis
Abstract Number: 1666

Incidence And Factors Associated With Serious Infections In Giant Cell Arteritis: Data From The ARTESER Registry
Abstract Number: 1667

Incidence and Predictors of Infection Following Rituximab Therapy in Patients With Autoimmune Rheumatic Diseases
Abstract Number: 1752

Incidence And Predictors Of Major Adverse Cardiovascular Events In Giant Cell Arteritis: Data From The ARTESER Multicentre Registry
Abstract Number: 1622

Incidence and Risk Factors of Radiologically Confirmed ILD in Patients with Psoriasis: An Underrecognized Association
Abstract Number: 1668

Incidence and risk of Herpes Zoster infection in Korean patients with rheumatoid arthritis treated with biologics, targeted synthetic and conventional synthetic DMARDs : Data from the KOBIO registry
Abstract Number: 1383

Incidence of Comorbidities and Causes of Mortality in Patients with Sjögren Disease in the Swedish Population Between 2006-2022
Abstract Number: 0793

Incidence of DXA in RA
Abstract Number: 1320

Incidence of Psoriatic Arthritis Among Patients With Psoriasis Treated With Targeted Synthetic and Biologic Therapies: A Propensity Score-Matched Real-World Cohort Study
Abstract Number: 1321

Incidence of Uveitis in Patients With Axial Spondyloarthritis Receiving Filgotinib in the TORTUGA and OLINGUITO Trials
Abstract Number: 1753

Incidence Rates, Prevalence, and Mortality of Systemic Sclerosis in the United States between 2017 and 2024: A Retrospective Observational Cohort Study
Abstract Number: 1191

Incident Arrhythmia-Related Outcomes After Systemic Sclerosis Diagnosis: A Propensity-Matched Retrospective Cohort Study
Abstract Number: 1411

Incident Cardiovascular, Thromboembolic, and Safety Outcomes of JAK Inhibitors Versus TNF Inhibitors in Seropositive Rheumatoid Arthritis: A Propensity Score-Matched Real-World Analysis
Abstract Number: 1226

Incident Lupus Nephritis After Anifrolumab Versus Belimumab in Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
Abstract Number: 2958

Incident Organ Involvement In FSR-SARC Patient Registry Patients with Self-Reported Bone Sarcoidosis Diagnosis
Abstract Number: 1754

Incident Pre-Diabetes Mellitus and Progression to Diabetes Mellitus with Glucocorticoid Exposure in US Veterans with Polymyalgia Rheumatica
Abstract Number: 0743

Inconsistent correlation between rheumatic immune related adverse event CTCAE grade, disease activity measures, and patient-reported outcomes
Abstract Number: 2256

Increased Arterial Stiffness in Younger and Low-Risk Individuals with Systemic Lupus Erythematosus Predicts Atherosclerotic Plaque Progression: A Matched Comparative Study with Rheumatoid Arthritis, Diabetes Mellitus, and Healthy Controls
Abstract Number: 1090

Increased Myeloid Clonal Hematopoiesis In Systemic Lupus Erythematosus
Abstract Number: 0316

Increased Prevalence of Diffuse Alveolar Hemorrhage in Three Cohorts of Male over Female Patients with Systemic Lupus Erythematosus
Abstract Number: 0492

Increased Proportion of ThA, an Age-associated Lymphocyte Subset, Correlates with Higher Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1192

Increased Risk of Multi-Organ Involvement in Asians Patients with Systemic Sclerosis (SSc) – Systemic Lupus Erythematous (SLE) Overlap Syndrome
Abstract Number: 1346

Increased risk of sudden sensorineural hearing loss in patients with ankylosing spondylitis: a nationwide cohort study
Abstract Number: 1512

Increasing Acquisition and Documentation of Pain Score, Patient Reported Outcome and Provider Globals in Juvenile Idiopathic Arthritis: A Quality Improvement Initiative
Abstract Number: 0271

Increasing Use of Plasmapheresis Without Survival Benefit: A Two-Decade Comparative Cohort Study of SLE-Associated Diffuse Alveolar Hemorrhage
Abstract Number: 2366

Incremental Direct and Indirect Costs of Sjögren’s Disease in the United States: A Retrospective Analysis Using MarketScan Databases
Abstract Number: 1269

Indirect Treatment Comparison of Belimumab Versus Obinutuzumab in MMF-Treated Patients with Active Proliferative Lupus Nephritis
Abstract Number: 1227

Indirect Treatment Comparison of Efficacy of Subcutaneous Anifrolumab Versus Intravenous Anifrolumab in Patients With Systemic Lupus Erythematosus
Abstract Number: 2334

Individual and Cumulative Impact of Depression, Anxiety and Obesity on Biologic and Targeted Synthetic DMARD therapy in Patients with Psoriatic Arthritis: A Longitudinal Cohort Study
Abstract Number: 0986

Induced pluripotent stem cell (iPSC)-derived cardiac microtissues as a modeling and drug testing platform for systemic sclerosis primary heart involvement
Abstract Number: 0714

Induction and Maintenance of Gout Remission During Intensive Urate-Lowering with Pegloticase: Post Hoc Analysis of a 2.5 Year Open-Label Extension Study
Abstract Number: 0010

Induction of B Cell Aplasia with cGP130 Armored-CAR T Cells Without Lymphodepletion
Abstract Number: 2648

Induction of Clinical Remission in Patients with Uncontrolled Gout Treated with Pegloticase and Immunomodulation: Experience in Two Community Rheumatology Practices
Abstract Number: 1786

Infection and Venous Thromboembolic Safety of Upadacitinib, Tofacitinib, and Tumor Necrosis Factor Inhibitors in Rheumatoid and Psoriatic Arthritis
Abstract Number: 0317

Infections and Mortality in Hospitalized Systemic Lupus Erythematosus Patients: A Study from a Peruvian Tertiary Hospital.
Abstract Number: 0900

Infectious Complications and Hypogammaglobulinemia Following Advanced B-Cell-Targeting Cellular Therapies in Immune-mediated Inflammatory Disease: A Systematic Review
Abstract Number: 1755

Infectious Mononucleosis associated with Increased Risk of Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 0758

Inflammation and Damage Are Distinct Imaging Phenotypes on High-Frequency Ultrasound in Juvenile Localized Scleroderma
Abstract Number: 0572

Inflammation and Endothelial Dysfunction Increase Cardiovascular Disease Risk in a Biopsychosocial Cohort of Juvenile-Onset Lupus and Dermatomyositis Patients
Abstract Number: 2000

Inflammation-independent Remodeling Defines a Renal Disease Axis in Systemic Lupus Erythematosus
Abstract Number: 1449

Inflammatory and Metabolic Biomarkers and Risk of Progression to Difficult-to-Treat Rheumatoid Arthritis
Abstract Number: 2434

Inflammatory but not lipid markers are independently associated with carotid plaque in rheumatoid arthritis
Abstract Number: 1450

Inflammatory Cytokines and Disease Activity in Rheumatoid Arthritis
Abstract Number: 2073

Inflammatory serum proteomic signature in primary Sjögren’s disease identifies shared clinical endotypes in systemic lupus erythematosus: results from the BISCIONE SjD cohort
Abstract Number: 2174

Influence of Damage Burden in Patient-Reported Health Outcomes in Early Systemic Sclerosis
Abstract Number: 0759

Influence of Sex and Ethnicity on Systemic Sclerosis Microangiopathy Assessed by Nailfold Capillaroscopy: A Quantitative Analysis in a Tertiary Cohort
Abstract Number: 1193

Infrared Pen for Quantification of Raynaud Phenomenon in Systemic Sclerosis
Abstract Number: 1451

Inhalational insults and trends in 10-year mortality in male rheumatoid arthritis patients: the combined impact of smoking and occupational vapors, gases, dusts, and fumes exposure
Abstract Number: 0174

Initial high-dose glucocorticoid therapy in takayasu arteritis is associated with delayed tapering but not with reduced relapse
Abstract Number: 2175

Initial Presentation Of Systemic Sclerosis (SSc) Defines Clinically Meaningful SSc Phenotypes
Abstract Number: 0272

Initial Results of GR1803 (BCMA×CD3 TCE) Therapy in Patients with Refractory Systemic Lupus Erythematosus: a Phase 1b/2a Study
Abstract Number: 1653

Initiation of Low-Dose Urate-Lowering Therapy During a Gout Flare Versus Deferred Initiation: A Pragmatic Randomized Trial
Abstract Number: 2578

Injectable therapies for lateral epicondylitis: a systematic review and network meta-analysis.
Abstract Number: 2858

Inorganic and Organic Dust Exposures Associated with Risk of Systemic Autoimmune Rheumatic Diseases in the Medicare-linked Agricultural Health Study Sub-Cohort
Abstract Number: 0318

Inpatient outcomes of acute venous thromboembolism in systemic lupus erythematosus and vasculitis: A National Inpatient Sample retrospective cohort study
Abstract Number: 0522

Insights into Lupus Research Participation from Patient and Family Voices: A Thematic Analysis of Involvement in Lupus Prevention Research
Abstract Number: 2752

Insufficient pharmacological management of rheumatoid arthritis in France in 2019: analysis based on the French National Health Data System (SNDS) – PREST study
Abstract Number: 0769

Insurance-Based Disparities in 30-Day Readmission After Lupus Nephritis Hospitalization: A National Readmissions Database Study
Abstract Number: 2667

Integrated Humoral and Inflammatory Profiling Characterizes SARS-CoV-2 Vaccine Responses in Immune-Mediated Inflammatory Diseases
Abstract Number: 2001

Integrated Immune and CD19⁺ B-Cell Transcriptomic Profiling Identifies a Distinct Signature in Serologically Active Clinically Quiescent SLE
Abstract Number: 1091

Integrated multi omics and machine learning identify diagnosis-independent endotypes and predictive clinical proteomic signatures in rheumatoid arthritis and systemic lupus erythematosus
Abstract Number: 0131

Integrated Serum Proteomics and Autoantibody Analyses Reveal a Biomarker Signature Predictive of Flare During Biologic Tapering in Rheumatoid Arthritis
Abstract Number: 2002

Integrated Single-Cell Multiomics Analysis Reveals Progressive Remodeling of Immune Circuits Across Preclinical Lupus Stages
Abstract Number: 0934

Integrated Stress Response Drives Endothelial Senescence and Vascular Remodeling in Antiphospholipid Syndrome Nephropathy
Abstract Number: 0493

Integrated Transcriptomic Analysis Identifies Rheumatoid Arthritis-Specific and Progression-Associated Synovial Gene Signatures
Abstract Number: 2003

Integrated Transcriptomic and Autoantibody Profiling in Systemic Lupus Erythematosus Associate with Distinct Organ-Specific Clinical Phenotypes
Abstract Number: 0044

Integrative Multi-Omic Profiling of Lupus Nephritis Reveals MicroRNA Master Regulators of Immune Pathogenesis and Class-Specific Biomarkers
Abstract Number: 1228

Intensified B-Cell Depletion in Lupus Nephritis INTONATE Randomized Trial
Abstract Number: 2556

Inter-Hip Femoral Neck T-Score Discordance on Bilateral DXA: A Retrospective Cross-Sectional Study
Abstract Number: 1043

Interactions between MAIT cells and the Microbiome in Rheumatoid Arthritis
Abstract Number: 1787

Interdisciplinary considerations for patients receiving CAR T cells for autoimmune diseases in the U.S. – lessons and resources
Abstract Number: 1471

Interest in Generative Artificial Intelligence (AI) Among Reproductive-Age Women with Systemic Autoimmune and Rheumatic Diseases
Abstract Number: 1020

Interferon Pathway-High Plasmacytoid Dendritic Cells Define Immune-Stromal Niches in Cutaneous Lupus
Abstract Number: 2012

Interferon Response Genes and Joint Damage in Psoriatic Arthritis: A Sex-Stratified Analysis
Abstract Number: 2045

Interferon Responsive Gene Expression Differentiates Macrophage Activation Syndrome Complicating Childhood-onset Systemic Lupus Erythematosus (cSLE) from active cSLE Alone
Abstract Number: 1991

Interferon-induced Protein 44-like Promoter Hypomethylation as an Epigenetic Hallmark of Systemic Lupus Erythematosus
Abstract Number: 1108

Interferon-α-Driven Stratification Reveals Metabolic Reprogramming of Double Negative, Naive and Transitional B cell subsets and Refines Molecular Classification in Sjögren’s Disease
Abstract Number: 0113

Interferon-γ Activates the GBP5-TSG6 Axis and Modulates Interleukin-1β-Induced Inflammatory Signaling Responses in Osteoarthritis Synovial Fibroblasts
Abstract Number: 1270

Interleukin-2 Is Associated with Cytopenias in Systemic Lupus Erythematosus
Abstract Number: 0494

Interleukin-6 may influence the association of lipoprotein(a) with coronary atherosclerosis in rheumatoid arthritis
Abstract Number: 0600

International Patient Perspectives on AI-Assisted Opportunistic Osteoporosis Screening: A Multicenter Qualitative Study
Abstract Number: 2019

Interpretable Chemical Fingerprinting of Human Synovial Biopsies in Inflammatory Arthritis Using Raman Hyperspectral Imaging and Spectral Unmixing
Abstract Number: 2784

Interstitial Lung Disease Care Patterns and Specialist Encounters in Patients with a Positive Rheumatoid Factor, Cyclic Citrullinated Peptide, or Anti-nuclear Antibodies: A Retrospective Observational Study
Abstract Number: 0202

Interstitial Lung Disease in ANCA Associated Vasculitis With and Without Kidney Involvement
Abstract Number: 0430

Interstitial Lung Disease in Primary Sjögren’s Disease: A Distinct Older-Age Phenotype Inversely Associated with C4 Consumption and Cryoglobulinemia
Abstract Number: 2435

Interstitial Lung Disease in Rheumatoid Arthritis: Survival Analysis Across Radiological Patterns
Abstract Number: 2111

Intraoperative Predictability of Temporal Artery Biopsy Outcomes In Giant Cell Arteritis
Abstract Number: 1271

Intravenous Cyclophosphamide Versus Mycophenolate Mofetil for Induction Therapy in Incident Lupus Nephritis: Data From a Multi-Ethnic, Multinational Latin American Cohort (GLADEL 2.0)
Abstract Number: 1005

Intrinsic Defects in Disease-Associated Microglia Contribute to Neuropsychiatric Manifestations of SLE
Abstract Number: 2087

IRF4hiKi67⁺ Plasmablast-Potent Age-Associated B Cells Are Expanded and Associated with Disease Duration in Rheumatoid Arthritis
Abstract Number: 0175

Is Image Remission By 18F-FDG PET/CT Possible In Patients With Giant Cell Arteritis: Importance of Delayed Imaging.
Abstract Number: 0005

Is the HLA-B*52 allele associated with an increased risk of developing Takayasu arteritis in Brazil? A Monocenter Cross-Sectional Study.
Abstract Number: 0715

Isolated, Metabolic, and Hypertensive Gout: A Population-Based Cluster Analysis of 94,759 Patients
Abstract Number: 2297

Ixekizumab and Concomitant Tirzepatide Achieved Early Disease Control in Adults with Psoriatic Arthritis and Obesity/Overweight: Phase 3b TOGETHER-PsA Trial
Abstract Number: 2942

Ixekizumab Plus Tirzepatide Demonstrated Greater Disease Control at 52 Weeks Versus Ixekizumab Alone With Incremental Improvement From Week 36 in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomised Clinical Trial
Abstract Number: 2298

Ixekizumab With Tirzepatide in Psoriasis or Psoriatic Arthritis: A Pooled Analysis of Phase 3b Randomized Controlled Trials
Abstract Number: 2299

Ixekizumab With Tirzepatide Was Associated With Reduced CV Risk Factors and Calculated CV Risk Beyond Ixekizumab Alone in Psoriatic Disease and Obesity